We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Afriag | LSE:AFRI | London | Ordinary Share | IM00B3VVCM89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.085 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
20 June 2019
AfriAg Global Plc
("AfriAg Global" or the "Company")
AfriAg commits to second phase of investment in to Apollon Formularies Ltd
AfriAg Global PLC, a company whose shares are admitted to trading on London’s NEX Exchange (Ticker: AFRI) advises that following shareholder approvals of the resolutions put to the Company’s shareholders yesterday, that it will be now proceeding to close the conditional placing of £700,000 as announced on 24 May 2019 and now plans to move towards its stated intention of increasing its investment in to Apollon Formularies Ltd (“AFL” or “Investee”) to 2.34%.
As previously announced, this second stage of investment in to AFL is a key step towards offering a full share-based offer for all outstanding shares in Apollon Formularies Ltd. Further investments in Apollon Formularies Ltd will subject to shareholder and regulatory approvals.
Also, with respect to the Company’s announcement of 17 June 2019, and for the avoidance of any doubt, AfriAg advises that:
About Apollon
Apollon is a Federally Licensed vertically integrated medical cannabis company operating in Jamaica. Its Retail (Therapeutic) Medical Cannabis Dispensary will be located at Doc’s Place wellness center at 42 One Love Drive in Negril, Jamaica, which is owned and operated by Doc’s Place International, Inc., an entity that Apollon Formularies Ltd has the right to acquire. Apollon offers a full suite of medical cannabis pharmaceutical products developed in its cultivation, processing and manufacturing facilities. Doc’s Place offers an all-inclusive, wellness resort that through its affiliation with Apollon is able to accommodate medical cannabis care and treatment involving Licensed Medical Doctors and other healthcare professionals. Apollon also has a contractual option to acquire 660 acres of prime agricultural land in Jamaica that it intends to use for its Tier-3 legal medical cannabis cultivation licence (greater than 5 acres).
Notice Regarding Forward-Looking Statements
This announcement includes "forward-looking statements" involving the Company, the other entities referenced in this announcement, and the respective subsidiaries, affiliates and associates of the Company and such other entities (collective, the “Involved Entities”), which include all statements other than statements of historical facts, including, without limitation, those regarding the financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the control of the Involved Entities that could cause the actual results, performance or achievements of the Involved Entities to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the present and future business strategies of the Involved Entities and the environment in which the Involved Entities will operate in the future. These forward-looking statements speak only as of the date of this announcement. The Company, on behalf of itself and each of the Involved Entities, expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in expectations of any Involved Entities with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.
The directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
For further information please contact:
AfriAg Global Plc: David Lenigas (Executive Chairman) |
+44 (0)20 7440 0640 |
Peterhouse Capital Limited Guy Miller Fungai Ndoro |
+44 (0)20 7469 0930 |
Trading in AfriAg Global Plc shares
AfriAg Global Plc is listed on London’s NEX Exchange under the ticker symbol AFRI.
NEX Exchange’s website is https://www.nexexchange.com
Many regulated entities in the UK now trade shares in companies on the NEX Exchange. These can be found at https://www.nexexchange.com/members-partners/brokers/
Copyright e 20 PR Newswire
1 Year Afriag Chart |
1 Month Afriag Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions